About Cassava Sciences, Inc. - Common Stock (SAVA)
Cassava Sciences Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, particularly Alzheimer's disease. The company aims to address unmet medical needs through its proprietary drug candidates, which are designed to enhance cognitive function and address the underlying biology of neurodegeneration. Cassava Sciences conducts rigorous research and clinical trials to advance its therapeutic solutions, with the vision of improving the quality of life for patients and their families affected by these challenging conditions. Read More
Peraso Inc. (NASDAQ: PRSO), a pioneer in mmWave wireless technology solutions, announced it has regained compliance with the Nasdaq Capital Market’s minimum bid price requirement. The notice from Nasdaq follows the company’s recent momentum in fixed wireless access (FWA), defense communications, transportation, and professional communication markets.
Cassava Sciences (NASDAQ: SAVA) witnessed a dramatic surge in its stock price today, climbing an impressive 18% after its President and CEO, Richard Barry, disclosed a significant personal investment in the company. The move, which saw Barry acquire hundreds of thousands of shares, has injected a much-needed dose of confidence
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Cassava Sciences shares are trading higher Tuesday morning. A Form 4 filing disclosed that CEO Rick Barry acquired 237,941 shares at an average price of $2.25 each.
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
AUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced management’s participation in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8 – 10, 2025 in New York City.
AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the second quarter ended June 30, 2025 and provided a business update.
AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced the appointment of Dr. Joseph Hulihan as Chief Medical Officer (CMO). Dr. Hulihan will devote approximately half of his professional time to Cassava, advising on the clinical development of simufilam, Cassava’s investigational candidate for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy.
AUSTIN, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel treatments for central nervous system (CNS) disorders, today reported positive preclinical results of a study evaluating simufilam in a well-accepted mouse model of tuberous sclerosis complex (TSC)-related epilepsy.
AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system (CNS) disorders such as tuberous sclerosis complex (TSC)-related epilepsy, today announced the retirement of James W. Kupiec, MD, Chief Medical Officer, effective May 9, 2025. The Company also appointed Jack Moore, PhD, as Senior Vice President, Clinical Development, reporting to Rick Barry, Chief Executive Officer.
The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said, while adding that the Alzheimer’s disease development program with Simufilam will be discontinued by the end of the second quarter of 2025.
